Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

and EYLEA fueled the company’s growth. Dupixent remains a major success, treating over a million patients worldwide, with potential for new uses. Meanwhile, Regeneron Pharmaceuticals ...

The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California, won the top award of $250,000 in the 2025 Regeneron Science Talent ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Regeneron has formed a corporate venture capital ... the onset of biosimilar competition to ophthalmology blockbuster Eylea (aflibercept), which is seeing sales start to fade.

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.

The best 4K Blu-ray players deliver the ultimate picture quality for watching movies and TV series at home. Although streaming services are popular, Blu-rays deliver video at a higher bitrate ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...